Emeryk A, Bartkowiak-Emeryk M. Safety and monitoring of allergen immunotherapy. Alergologia Polska - Polish Journal of Allergology. 2019;6(2):49-52. doi:10.5114/pja.2019.86348.
APA
Emeryk, A., & Bartkowiak-Emeryk, M. (2019). Safety and monitoring of allergen immunotherapy. Alergologia Polska - Polish Journal of Allergology, 6(2), 49-52. https://doi.org/10.5114/pja.2019.86348
Chicago
Emeryk, Andrzej, and Małgorzata Bartkowiak-Emeryk. 2019. "Safety and monitoring of allergen immunotherapy". Alergologia Polska - Polish Journal of Allergology 6 (2): 49-52. doi:10.5114/pja.2019.86348.
Harvard
Emeryk, A., and Bartkowiak-Emeryk, M. (2019). Safety and monitoring of allergen immunotherapy. Alergologia Polska - Polish Journal of Allergology, 6(2), pp.49-52. https://doi.org/10.5114/pja.2019.86348
MLA
Emeryk, Andrzej et al. "Safety and monitoring of allergen immunotherapy." Alergologia Polska - Polish Journal of Allergology, vol. 6, no. 2, 2019, pp. 49-52. doi:10.5114/pja.2019.86348.
Vancouver
Emeryk A, Bartkowiak-Emeryk M. Safety and monitoring of allergen immunotherapy. Alergologia Polska - Polish Journal of Allergology. 2019;6(2):49-52. doi:10.5114/pja.2019.86348.
The article presents the factors determining the safety of allergen immunotherapy (AIT) in patients with allergic rhinitis, asthma and hymenoptera-sensitized venoms. The most important rules of conduct that increase the safety of AIT are given.
